LOW-OGESTREL-28 Suppliers: Who Manufactures the Low-Ogestrel 28-Day Oral Contraceptive and What Are the Supply Risks?
LOW-OGESTREL-28 is an oral contraceptive product packaged for the “28-day” regimen. No verifiable supplier/manufacturer dataset for this specific NDC/product label (“LOW-OGESTREL-28”) is available in the supplied information, so a complete and accurate supplier map cannot be produced.
Which companies supply LOW-OGESTREL-28 to pharmacies and wholesalers?
Featured answer: Not determinable from the provided inputs.
What “LOW-OGESTREL-28” maps to at the NDC/label level
Supplier identification for a specific drug product is usually anchored to the NDC, labeler, and application holder (e.g., ANDA/BLA/505(b)(2) holder).
Without the product’s exact NDC or Orange Book/Drug Listing identifier, supplier attribution cannot be performed.
What is the Orange Book status of LOW-OGESTREL-28 and how does it affect supplier availability?
Featured answer: Not determinable from the provided inputs.
Why Orange Book data matters for supply
Orange Book listings identify application holders tied to manufacturing authorization and exclusivity.
That linkage is the basis for mapping upstream suppliers, authorized generics, and licensing-driven sourcing.
Who manufactures the active ingredient and tablet strengths used in LOW-OGESTREL-28?
Featured answer: Not determinable from the provided inputs.
Ingredient-to-finished-product attribution
“Supplier” can mean:
API manufacturer(s) for ethinyl estradiol and a progestin (product-dependent),
finished-dose manufacturer,
packager/labeler.
Without a label/NDC-to-application mapping, none can be stated.
How many supplier sources exist for LOW-OGESTREL-28, and where are they located?
Featured answer: Not determinable from the provided inputs.
Consolidation and single-site manufacturing risk
Multi-source availability is typically derived from:
NDC count across labelers,
FDA CDER supplier approvals for dosage forms,
confirmed manufacturing sites.
None of these inputs are present.
What generic or authorized-generic products compete with LOW-OGESTREL-28 in supply?
Featured answer: Not determinable from the provided inputs.
Substitution risk that changes supplier flow
Substitution depends on:
active ingredient/mg equivalents,
regimen schedule (21/7 vs 24/4 vs 28-day),
tablet color/identifiers.
Without the exact product composition and NDC, competition cannot be mapped.
What FDA filings or manufacturing changes could disrupt LOW-OGESTREL-28 supply?
Featured answer: Not determinable from the provided inputs.
Manufacturing disruption signals used by buyers
FDA approvals for manufacturing site changes
drug shortage notifications
facility enforcement actions
recalls tied to specific lots/NDCs
None are provided.
Key Takeaways
Supplier identification for LOW-OGESTREL-28 cannot be completed without a product identifier that links the label to an NDC and FDA application holder.
FAQs
How do I identify the finished-dose manufacturer behind an oral contraceptive label like LOW-OGESTREL-28?
What data field in FDA systems is required to map an NDC to a supplier and labeler?
How do I distinguish API suppliers from finished-dose manufacturers for a packaged oral contraceptive?
What indicators from FDA sources usually predict supply constraints for generic oral contraceptives?
How does authorized-generic status change the supplier and wholesaler network for oral contraceptives?
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
